Advances in diabetes technology have radically transformed the treatment paradigm for type 1 diabetes (T1D), yet, glycemic outcomes continue to be suboptimal, and the burden of disease is high.1 Automated insulin delivery or hybrid closed-loop (HCL) systems have proven to be safe and effective for patients with T1D, demonstrating marked improvement in the percentage of time in target range, 70–180 mg/dL, by 10%–11% or 2.6 h more per day compared to sensor-augmented pump therapy2,3 and reduction in hypoglycemia at various thresholds. The gene discussed is INS; the disease is type 1 diabetes mellitus.